NCT02837692View on ClinicalTrials.gov

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

June 8, 2016

Primary Completion Date

September 7, 2017

Study Completion Date

September 11, 2017

Conditions
Healthy
Interventions
DRUG

JNJ-42847922 10 milligram (mg)

JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.

DRUG

JNJ-42847922 20 mg

JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.

DRUG

JNJ-42847922 40 mg

JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.

DRUG

JNJ-42847922 60 or 80 mg

JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.

Trial Locations (2)

Unknown

Cypress

Knoxville

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02837692 - A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults | Biotech Hunter | Biotech Hunter